KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Retained Earnings (2016 - 2025)

Alnylam Pharmaceuticals' Retained Earnings history spans 17 years, with the latest figure at -$20.1 million for Q4 2025.

  • For Q4 2025, Retained Earnings rose 99.72% year-over-year to -$20.1 million; the TTM value through Dec 2025 reached -$20.1 million, up 99.72%, while the annual FY2025 figure was -$20.1 million, 99.72% up from the prior year.
  • Retained Earnings reached -$20.1 million in Q4 2025 per ALNY's latest filing, up from -$21.8 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$20.1 million in Q4 2025 to a low of -$7.4 billion in Q2 2025.
  • Average Retained Earnings over 5 years is -$3.3 billion, with a median of -$2.4 billion recorded in 2021.
  • Peak YoY movement for Retained Earnings: crashed 31077.53% in 2024, then soared 99.72% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$33.3 million in 2021, then plummeted by 34.26% to -$44.7 million in 2022, then skyrocketed by 47.65% to -$23.4 million in 2023, then plummeted by 31077.53% to -$7.3 billion in 2024, then skyrocketed by 99.72% to -$20.1 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Retained Earnings are -$20.1 million (Q4 2025), -$21.8 million (Q3 2025), and -$7.4 billion (Q2 2025).